The Use of Hematopoietic Growth Factors in HIV Infection and AIDS-Related Malignancies

References

• Folks T M, Kessler S W, Orenstein JM, et al. Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow. Science 1988; 242: 919–922
   PubMed Web of Science ®Google Scholar
• Rosenberg Z F, Fauci AS. The immunopathogenesis of HIV infection. Adv Immunol 1989; 47: 377–431
   PubMed Web of Science ®Google Scholar
• Meltzer M S, Gendelman HE. Effects of colony stimulating factors on the interaction of monocytes and the human immunodeficiency virus. Immunol Lett 1988; 19: 193–198
   PubMed Web of Science ®Google Scholar
• Molina JM, Scadden D T, Amirault C, et al. Human immunodeficiency virus does not induce interleukin-1, interleukin-6, or tumor necrosis factor in mononuclear cells. J Virol 1990; 64: 2901–2906
   PubMed Web of Science ®Google Scholar
• Katz H D, Mitsuyasu R, Gottliet MS, et al. Mechanism of defective NK cell acivity in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. II. Normal antibodydependent cellular cytotoxicity (ADCC) mediated by effector cells defective in natural killer (NK) cytotoxicity. J Immunol 1987; 139: 55–60
   PubMed Web of Science ®Google Scholar
• Fauci AS. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science 1988; 239: 617–622
   PubMed Web of Science ®Google Scholar
• Donahue R E, Johnson M M, Zon LI, et al. Suppression in vitro hematopoiesis following human imunodeficiency virus infection. Nature 1987; 326: 200–203
   PubMed Web of Science ®Google Scholar
• Kopelman R G, Zolla-Pazner S. Association of human immunodeficiency virus infection and autoimmune phenomena. Am J Med 1988; 84: 82–88
   PubMed Web of Science ®Google Scholar
• Levine AM. Lymphoma in acquired immunodeficiency syndrome. Sem Oncol 1990; 17: 104–112
   PubMed Web of Science ®Google Scholar
• Groopman J E, Mitsuyasu R T, DeLeo MJ, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med 1987; 317: 593–5983
   PubMed Web of Science ®Google Scholar
• Baldwin C G, Gasson J C, Quan SG, et al. GM-CSF enhances neutrophil function in AIDS patients. Proc Natl Acad Sci (USA) 1988; 85: 2763–2766
   PubMed Web of Science ®Google Scholar
• Mitsuyasu R, Levine J, Miles SA, et al. Effects of long term subcutaneous (SC) administration of recombinant granulocytemacrophage colony-stimulating fator (GM-CSF) in patients with HIV-related leukopenia. Blood 1988; 72: 357, suppl 1, abstr
   Google Scholar
• Richman D D, Fischl M A, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: A double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 192–197
   PubMed Web of Science ®Google Scholar
• Volberding P A, Lagakos S W, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases (see comments). N Engl J Med 1990; 322: 941–949
   PubMed Web of Science ®Google Scholar
• Fischl M A, Richman D, Uanchandani D, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: A double-blind, placebo-controlled trial. N Engl J Med 1987; 317: 185–191
   PubMed Web of Science ®Google Scholar
• Perno C, Yarchoan R, Cooney DA, et al. Replication of human immunodeficiency virus in monocytes. GM-CSF potentiates viral production yet enhances the antiviral effect mediated by AZT and other dideoxynucleoside congeners of thymidine. J Exp Med 1989; 169: 933–951
   PubMed Web of Science ®Google Scholar
• Hammer S M, Gillis JM. Synergistic activity of granulocytemacrophage colony-stimulating factor and 3′-azido-3′-deoxythymidine against human immunodeficiency virus in vitro. Antimicrob Agents Chemother 1987; 31: 1046–1050
   PubMed Web of Science ®Google Scholar
• Bhalla K, Birhofer M, Grant S, Graham. The effect of recombinant human GM-CSF on AZT-mediated biochemical and cytotoxic effects on normal human myeloid progenitor cells. Exp Hematol 1989; 17: 17–20
   PubMed Web of Science ®Google Scholar
• Levine J D, Allan J D, Tessitore JH, et al. Granulocyte-macrophase colony stimulating factor ameliorates that neutropenia induced by azidothymidine in AIDS/ARC patients. Proc Am Soc Clin One 1989; 8: 1, abstr
   Google Scholar
• Grossberg H S, Bonnem E M, Buhles WC. GM-CSF with ganciclovir for the treament of CMV retinitis in AIDS (Letter). N Engl J Med 1989; 320: 1560
   PubMed Web of Science ®Google Scholar
• Hardy D, Spector S, Polsky B, et al (1990) Safety and efficacy of combined ganciclover (GCV) and granulocyte-macrophage stimulating factor (GM-CSF) vs. ganciclovir alone for CMV retinitis in AIDS (ACTG 073): a preliminary report. Proceedings VI International Conference on AIDS: AIDS in the Nineties: From Science to Policy, San Francisco, June 19–24, 1990. Moscone Center, California, F.B.92 abstr
   Google Scholar
• Berman E, Duigou-Osterndorf R, Krown SE, et al. Synergistic cytotoxic effect of azidothymidine and recombinant interferon alpha on normal human bone marrow progenitor cells. Blood 1989; 74: 1281–1286
   PubMed Web of Science ®Google Scholar
• Krown S E, Gold J WM, Niedzwiecki D, et al. Interferon-α with zidovudine: Safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency syndrome (AIDS). An Int Med 1990; 112: 812–821
   PubMed Web of Science ®Google Scholar
• Davey R T, Jr, Davey V, Zurlo J, et al (1990) A phase I/II trial of zidovudine, interferon alpha, and granulocyte-macrophage colony stimulating factor in treatment of HIV infection. Proceedings VI International Conference on AIDS: AIDS in the Nineties: from Science to Policy, San Francisco, June 19–24, 1990. Moscone Center: S.B., CaliforniaUSA, 420, abstr
   Google Scholar
• Mitsuyasu RT. AIDS-related Kaposi's sarcoma: a review of its pathogenesis and treatment. Blood Rev 1988; 2: 222–231
   PubMed Web of Science ®Google Scholar
• Gill P S, Akil B, Colletti P, et al. Pulmonary Kaposi's sarcoma: clinical findings and results of therapy. Am J Med 1989; 87: 57–61
   PubMed Web of Science ®Google Scholar
• Miles S A, Wang H J, Cortes E, et al. Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). A phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infections. Ann Inter Med 1990; 112: 582–589
   PubMed Web of Science ®Google Scholar
• Krown SE. Approaches to interferon combination therapy in the treatment of AIDS. Sem Oncol 1990; 17: 11–15, 1 Suppl 1, discussion 38–41
   PubMed Web of Science ®Google Scholar
• Fischl M, Reese J, Dearmasl, et al. Phase I study of interferonalpha and AZT in patients with AIDS-related Kaposi's sarcoma. IV International Conference AIDS 1988; 253, abstr
   Google Scholar
• Fischl M A, Uttanchandani R, Gagnon S, et al (1989) Phase I study of interferon alpha-2b(Intron), zidovudine and rGM-CSF in patients with AIDS-associated Kaposi's sarcoma. Proceedings V International Conference on AIDS: The Scientific and Social Challenge, Montreal, QuebecCanada, June 4–9, 1989. International Development Research Center, Ottawa, 342, abstr
   Google Scholar
• Scadden D, Bering H, Levine J, et al. Combined AZT/Interferonalpha/GM-CSF for AIDS-associated Kaposi's sarcoma (KS). Blood 1989; 74: 127, abstr
   Google Scholar
• Gill P S, Levine A M, Krailo M, et al. AIDS-related malignant lymphoma: results of prospective treatment trials. J Clin Oncol 1987; 5: 1322–1328
   PubMed Web of Science ®Google Scholar
• Walsh C, Werna J, Laubenstein L, et al. Phase I study of mBACOD and GM-CSF n AIDS-associated non-Hodgkin's lympoma (NHL): Preliminary results. Blood 1989; 74: 126a, abstr
   Google Scholar
• Kaplan L D, Kahn J O, Grossberg H, Volberding PA (1989) Chemotherapy with or without rGM-CSF in patients with AIDS-associated non-Hodgkin's lymphoma (NHL). Proceedings V International Conference on AIDS: The Scientific and Social Challenge, Montreal, QuebecCanada, June 4–9, 1989. International Development Research Center, Ottawa, 334, abstr
   Google Scholar
• Spivak J L, Barnes D C, Fuchs E, Quinn TC. Serum immunoreactive erythropoietin in HIV-infected patients. JAMA 1989; 261: 3104–3117
   PubMed Web of Science ®Google Scholar
• Fisch M, Galpin J E, Levine JD, et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 1990; 322: 1488–1493
   PubMed Web of Science ®Google Scholar
• Rarick M, Wilson E, Bernstein-Singer M, et al (1989) Double-blind placebo controlled study of recombinant human erythropoietin in AIDS patients with anemia caused by HIV infection and zidovudine. Proceedings V International Conference on AIDS: The Scientific and Social Challenge, Montreal, QuebecCanada, June 4–9, 1989. International Development Research Center, Ottawa, 195, abstr
   Google Scholar
• Abels R, personal communication
   Google Scholar
• Koyanagi Y, O'Brien W A, Zhao JQ, et al. Cytokines alter production of HIV-1 from primary mononuclear phagocytes. Science 1988; 241: 1673–1675
   PubMed Web of Science ®Google Scholar
• Miles S A, Mitsuyasu R, Fink N, et al (1989) Recombinant G-CSF and recombinant erythropoietin may abrogate the neutropenia and anemia of AIDS and may allow resumption of AZT. Proceedings V International Conference on AIDS: The Scientific and Social Challenge, Montreal, QuebecCanada, June 4–9, 1989. International Development Research Center, Ottawa, 550, abstr
   Google Scholar